Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast
1999
p53 Autoantibodies in Breast Cancer Patients
Sample size: 43
publication
Author Information
Author(s): Regele S, Kohlberger P, Vogl F D, Böhm W, Kreienberg R, Runnebaum I B
Primary Institution: Department of Obstetrics and Gynaecology, University of Ulm
Hypothesis
Do patients with minimal lesions of ductal carcinoma in situ of the breast have p53 autoantibodies?
Conclusion
A small percentage of patients with ductal carcinoma in situ of the breast had p53 autoantibodies, but there was no correlation with other clinical factors.
Supporting Evidence
- 11.6% of patients with ductal carcinoma in situ had p53 autoantibodies.
- Three seropositive patients had tumor sizes of 5 mm or less.
- No association was found between p53 autoantibody status and various clinical factors.
Takeaway
Some people with a type of breast cancer have special proteins in their blood, but it doesn't seem to relate to how serious their cancer is.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website